Pyxis Oncology, Inc. - 8-K Filing

Pyxis Oncology reports updated Phase 1 MICVO data showing 39% confirmed ORR and 6.7 month mPFS in R/M HNSCC patients. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PYXS

Read the full article at SEC EDGAR

Part of the story CG Oncology, Inc. - 8-K Filing (4 articles)

More Regulatory news